Blog
In 2023, the FDA granted approval to 13 new oncology drugs, constituting ~24% of the total approvals for the year
First-in-Class Therapies: AstraZeneca’s Capivasertib (Truqap): first AKT inhibitor approved for hormone-receptor-positive, HER2-negative metastatic breast cancer. Its approval alongside a companion diagnostic for PIK3CA, AKT1, or PTEN alterations; precision medicine...
Plasmatic IL8 as COPD biomarker response to PDE treatments? A very promising tool!
“The study by Govoni and colleagues (Govoni M, Bassi M, Santoro D, Donegan S, Singh D. Serum interleukin-8 as a determinant of response to PDE4 inhibition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2023; 208:559–569.) opens a new field of...
Started in oncology and opening a new era in CNS and beyond!
Many CNS diseases lack curative or disease-modifying treatments and represent a growing burden to healthcare systems and societies worldwide. These diseases are often multifactorial and complex in nature, with significant individual variability in the underlying...